2024-10-06 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis

**1. Performance Comparison**

Merck & Co Inc (MRK) is a pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

MRK's cumulative return stands at 71.19%, lagging behind the S&P 500 (VOO) with a cumulative return of 131.01%. This results in a **-59.82%** divergence, placing MRK's performance at the **24.66%** percentile compared to its historical performance against the S&P 500.

**2. Recent Price Action**

* **Closing Price:** $110.18
* **5-Day Moving Average:** $112.85
* **20-Day Moving Average:** $115.32
* **60-Day Moving Average:** $117.56

The current price is below all three moving averages, indicating potential downward pressure.

**3. Technical Indicators**

* **RSI:** 30.86 - This suggests the stock is currently in oversold territory.
* **PPO:** -0.42 - A negative PPO indicates a bearish trend.
* **Delta_Previous_Relative_Divergence:** -18.52 - This indicates a recent decline in the stock's relative performance compared to the S&P 500.
* **Expected Return:** 0.0% -  The expected return over the next 5 years is currently projected to be at a 0% excess return compared to the S&P 500 (VOO).

**4. Recent Earnings & Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings report (2024-08-05) saw an EPS of 2.15, surpassing the analysts' expectation of 1.88, with revenue reaching 16.11 B$ compared to the expected 15.78 B$. The exceeding expectations suggest positive sentiment regarding the company's growth trajectory. 

**5. News & Recent Issues**

According to FINBOLD, recent market outlook for MRK highlights the company's strong financial performance, particularly its revenue growth and pipeline development. Analysts remain optimistic about the company's long-term prospects, with many citing the strong performance of its blockbuster drug Keytruda as a key driver. However, some concerns remain regarding competition and the potential impact of rising healthcare costs. 

**6. Overall Analysis**

MRK is currently underperforming the broader market, indicated by its negative divergence compared to the S&P 500. While the stock is currently oversold and recent earnings have exceeded expectations, the downward trend in price action and negative PPO suggests potential for further decline. However, the company's strong financial performance, strong product pipeline, and continued success of Keytruda provide a foundation for future growth.

**7. Conclusion**

MRK presents a mixed picture with both positive and negative aspects. While the recent earnings performance has been strong, the stock's current position suggests cautious optimism. Investors should monitor the company's future performance and any potential changes in its competitive landscape before making investment decisions.  
